VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Provided By GlobeNewswire
Last update: Jun 5, 2024
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo
Top-line data from the 24-week double-blind portion of the trial expected in mid-2025
Read more at globenewswire.com
